River Road Asset Management LLC Buys New Holdings in Envista Holdings Co. (NYSE:NVST)

River Road Asset Management LLC bought a new stake in shares of Envista Holdings Co. (NYSE:NVST) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,283,073 shares of the company’s stock, valued at approximately $54,931,000. River Road Asset Management LLC owned 1.33% of Envista at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NVST. Headinvest LLC purchased a new stake in Envista in the 3rd quarter worth approximately $28,000. Fifth Third Bancorp lifted its holdings in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after buying an additional 621 shares during the period. Eagle Bay Advisors LLC purchased a new stake in Envista in the 2nd quarter worth approximately $35,000. Belpointe Asset Management LLC lifted its holdings in Envista by 80.6% in the 1st quarter. Belpointe Asset Management LLC now owns 901 shares of the company’s stock worth $37,000 after buying an additional 402 shares during the period. Finally, Itau Unibanco Holding S.A. purchased a new stake in Envista in the 3rd quarter worth approximately $47,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NVST shares. SVB Leerink started coverage on Envista in a report on Monday, February 26th. They issued an “underperform” rating and a $19.00 price objective for the company. Jefferies Financial Group cut Envista from a “buy” rating to a “hold” rating and lowered their target price for the company from $30.00 to $23.00 in a research note on Friday, February 9th. Leerink Partnrs restated an “underperform” rating on shares of Envista in a research note on Monday, February 26th. William Blair cut Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Finally, UBS Group assumed coverage on Envista in a research note on Friday, January 5th. They issued a “neutral” rating and a $26.00 target price for the company. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Envista presently has a consensus rating of “Hold” and a consensus target price of $29.60.

Envista Stock Down 1.0 %

Shares of Envista stock traded down $0.19 on Wednesday, reaching $19.59. The company’s stock had a trading volume of 1,891,911 shares, compared to its average volume of 2,378,082. The company has a market capitalization of $3.37 billion, a price-to-earnings ratio of -32.43, a P/E/G ratio of 3.57 and a beta of 1.35. The firm’s fifty day simple moving average is $21.36 and its two-hundred day simple moving average is $23.03. Envista Holdings Co. has a 52 week low of $18.95 and a 52 week high of $39.28. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The business had revenue of $645.60 million during the quarter, compared to the consensus estimate of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.52 EPS. Equities analysts anticipate that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.